Orion Corp New B Shs (ORINF) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon and welcome to Orion's full year 2025 result webcast and conference call. My name is Tuukka Hirvonen. I am the head of IR here at Orion. In a few moments, our CEO Liisa Hurme will present the results for the full year and Q4 last year, after which you will have the possibility to ask questions from Liisa and also from our CFO René Lindell. We will be first taking questions through the conference call lines and after that we will turn to the webcast. So through the webcast you have the possibility to type in your questions through the chat function of the webcast. Just before I let Liisa take over, I'd like to draw your attention to this usual disclaimer regarding future forward-looking statements. And with this short note, it's my pleasure to invite Liisa to the podium. Liisa, please. Thank you, Tuukka. And welcome on my behalf as well. I'll start with the Q4 and with some highlights during the last three months of last year. It's my pleasure to say that all our business divisions had a strong quarter and performed extremely well. Also, we received 180 million sales milestone from Bayer related to Nubeka. And we were able to proceed with our clinical pipeline by initiating phase two program with ODM212 molecule in our oncology pipeline. And also our partner Tenax in the United States initiated phase three trial called level two with levosimendan for pulmonary hypertension. And Q4 highlights the base business during Q4 compared to the previous year grew 18.5% and 60% when we include the previously mentioned milestone. And operating profit growth was 59% and including the milestone 254%, bringing us to 47% operating profit margin in Q4. Operating cash flow per share was slightly lower than previous year, and that's mainly due to the timing of royalty pay...